yahoo_financeOriginal article
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Data ReadoutTRUTAKNAPositive
AI Analysis
Summary
Vera Therapeutics announced that the ORIGIN 3 final efficacy analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy will be presented as a featured late-breaking oral presentation at the opening plenary session of ASN Kidney Week 2026.
Clinical Trial Data
Outcome Details
ORIGIN 3 final efficacy analysis will be presented as featured late-breaking oral presentation at ASN Kidney Week 2026
Importance:6/10
Sentiment:
0.40
clinical_trialdata_presentationconferenceORIGIN_3IgA_Nephropathy
Related Companies
Read the original article
Published by yahoo_finance on October 2, 2026 1:24 PM